Drug name - Xigduo Xr

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(7 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
M Feb 22, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 29 October, 2014

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.